Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibandronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 19/20 | 0.90 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.90 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.90 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.90 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.90 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibandronic Acid SCHEMBL365290 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1240197 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3415425 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL28564280 | 0.98 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3624745 | 0.97 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3630021 | 0.97 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3628878 | 0.97 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1579193 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3419518 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL27857197 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| EP-2416756-A2 | STABLE PHARMACEUTICAL COMPOSITIONS WITH HIGH BIOAVAILIBILITY | Bilgic, Mahmut (TR) | 2012-02-15 | — | — | EP | claimed |
| WO-2010117346-A2 | STABLE PHARMACEUTICAL COMPOSITIONS WITH HIGH BIOAVAILIBILITY | BILGIC MAHMUT (TR) | 2010-10-14 | — | — | WO | claimed |
| US-20090035315-A1 | Method of Improving Treatments in Rheumatic and Arthritic Diseases | OSTEOLOGIX A/S (DK) | 2009-02-05 | — | — | US | claimed |
| US-20080317849-A1 | Method for Improving the Medical Treatment of Pain | OSTEOLOGIX A/S (DK) | 2008-12-25 | — | — | US | claimed |
| WO-2007149815-A1 | STRONTIUM COMPOSITIONS AND METHODS OF TREATING ARTHRITIC AND OR OSTEOPORITIC CONDITIONS | THERAGENEX, LLC (US) | 2007-12-27 | — | — | WO | claimed |
| WO-2007149816-A2 | STRONTIUM COMPOSITIONS AND METHODS OF TREATING OSTEOPOROTIC CONDITIONS | THERAGENEX, LLC (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070292535-A1 | Strontium compositions and methods of treating arthritic and or osteoporitic conditions | TRX PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | claimed |
| US-20070292529-A1 | Strontium compositions and methods of treating osteoporotic conditions | TRX PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | claimed |
| EP-1758652-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| EP-1758653-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123192-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| CN-110366597-B | Blood profiling with protease inhibitors | 善威生物私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240060997-A1 | Blood Preparation and Profiling | SANGUI BIO PTY LTD (AU) | 2024-02-22 | — | — | US | disclosed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | FDPS 2981/4885GGPS1 3104/4885AGTR1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.